Actively Recruiting
Enabling Genomic Testing in Cancer of Unknown Primary
Led by The Christie NHS Foundation Trust · Updated on 2026-03-25
100
Participants Needed
6
Research Sites
171 weeks
Total Duration
On this page
Sponsors
T
The Christie NHS Foundation Trust
Lead Sponsor
N
National Institute for Health Research, United Kingdom
Collaborating Sponsor
AI-Summary
What this Trial Is About
Cancer of Unknown Primary (CUP) is where cancer cells are found in the body but the place the cancer began is not known. It is the 6th leading cause of cancer death in the UK and the prognosis is poor with a median survival of 6-9 months. There is a higher than average incidence of CUP in the North West (NW) of England (population of 7.4 million). Precision medicine has transformed treatment strategies in known tumour types, however in CUP there remains an urgent need to better understand CUP molecular characteristics to establish potential roles for novel therapeutic strategies. Treatment options remain limited due to difficulties in determining the primary site of the tumour and the lack of access to validated biomarkers. Access to good-quality tissue for molecular profiling remains a huge challenge in CUP. The emergence of liquid biopsies (sequence DNA in a blood test) as a source of biomarkers is also gaining rapid ground and this study aims to explore the potential utility of liquid biopsies in CUP.
CONDITIONS
Official Title
Enabling Genomic Testing in Cancer of Unknown Primary
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 16 years or over
- Provided written informed consent according to ICH/GCP and national regulations
- ECOG Performance status of 0 to 2
- Confirmed diagnosis of Cancer of Unknown Primary following ESMO guidelines, including local pathology reports and multidisciplinary team confirmation
- Availability of archival tumour histological report
- Willingness to provide blood samples on up to two occasions during the study
You will not qualify if you...
- Immunohistochemistry profile indicating a definitive primary cancer with specific treatment
- Known positive status for HIV, Hepatitis B, or Hepatitis C
- Unable to provide fully informed written consent
- Any medical, psychological, familial, or social condition that may interfere with study compliance and follow-up
- Bleeding disorders unless anticoagulation can be safely managed for blood sampling
- Conditions that increase risks related to blood sampling for the patient or investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
The Christie NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom, M20 4BX
Actively Recruiting
2
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, Merseyside, United Kingdom
Actively Recruiting
3
Blackpool Teaching Hospitals NHS Foundation Trust
Blackpool, United Kingdom
Actively Recruiting
4
Northern Care Alliance NHS Foundation Trust
Manchester, United Kingdom
Actively Recruiting
5
University Hospitals of Morecambe Bay NHS Trust
Morecambe, United Kingdom
Actively Recruiting
6
Lancashire Teaching Hospitals NHS Foundation Trust
Preston, United Kingdom
Actively Recruiting
Research Team
E
EGG CUP Study Team
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here